Axelopran
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
949904-48-7 949904-50-1 (sulfate) |
| PubChem (CID) | 67156338 |
| ChemSpider | 31444004 |
| Chemical and physical data | |
| Formula | C26H39N3O4 |
| Molar mass | 457.60556 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma for the treatment of opioid-induced constipation. It acts as a potent, selective, and peripherally-restricted μ-, κ-, and δ-opioid receptor antagonist, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract in vivo, and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration.[1]
See also
References
- ↑ , Axelopran (td-1211) briefing document anesthetic and analgesic drug products advisory committee June 11 and 12, 2014.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.